SBIR/STTR Research Award

Type-7: Fertility Protection in Cancer: Recovery of Whole Ovaries enabled by Next Gen Perfusion, Cryoprotection, and Nanowarming

Award identifier 1cc87d79c8c7d4469acdc9be8e62a21d2148c84e5bc3ceef7e1ed525cad02a4cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$2,323,053

Program and phase

SBIR · Phase II

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
EXPANSE BIO LLC
Proposal award date
2019-08-08
Contract end date
2024-12-31
UEI
Q1RBL5JSKJ75
Solicitation number
PA18-574
Topic code
100

Research abstract

There is a need and opportunity to improve the lives of the many tens of thousands of young cancer survivors annually, who face lifelong hormone imbalance and infertility due to cancer treatments that damage their reproductive organs. Ovary banking and autotransplantation has been proposed as a method to avoid irreversible damage, yet no clinical method exists to keep whole ovaries viable until re-implantation. Using carefully optimized protocols and effective cryoprotective agents, our team and others have successfully cryopreserved multiple tissues in an ice-free vitreous “glassy” or “amorphous” state, allowing for indefinite storage. Unfortunately, these advances in ice- free preservation had not been matched by similar advances to prevent damage from ice growth and/or fracturing during rewarming preventing viable banking. Recently, however, our Co-PI, Dr Bischof, demonstrated a scalable and biocompatible nanowarming technology using radiofrequency (RF)-excited iron oxide nanoparticles (IONPs) for ice and fracture avoidance that we demonstrated proof of concept of for vascularized whole ovaries during phase 1 and after. This program works to preserve fertility and hormone function for cancer survivors by developing nanowarming enabled cryobanking of whole human ovaries and ovarian tissue strips, for re-plantation following damaging chemo and radiation therapies. Combining nanowarming with recent advances in machine perfusion, optimized loading/unloading procedures, next generation non-toxic cryopreservation solutions, computational modeling, and powerful tissue imaging (e.g. cryomacroscopy, uCT, SWIFT-MRI), our approach leverages a convergence of state-of-the-art technologies to develop a comprehensive preservation protocol for reproductive organ protection that will maximize tissue viability. Building on the success in the feasibility phase, this project will deliver two primary products: (i) improved vitrification and re-warming strategy (compared to current gold-standard slow freezing) for preservation and banking of ovarian tissues for transplantation, (ii) comprehensive tools (including multi-thermic perfusion system), and protocol for recovery and successful banking and nanowarming of whole human ovaries to ultimately support whole ovary re-plantation (not possible with current methods). In addition, this project provides tools, equipment, solutions and protocols with highly- translatable technology toward banking of whole vital organs, and other vascular grafts, addressing widespread needs for breakthroughs in preservation – from improved cell and biospecimen preservation to whole organ banking. The project’s initial focus is to optimize preservation of human ovarian tissue strips followed by development of a comprehensive banking strategy for whole human ovaries. We will validate early in vitro success in two transplant models: (1) xenotransplantation of human ovarian tissue strips in nude mice, and (2) minimally invasive autotransplantation of nonhuman primate ovarian tissue strips from whole cryopreserved ovaries. Based on the results from Phase 1 with whole ovaries, and subsequent studies since then, we believe that we are close to a successful protocol for indefinite preservation of ovaries. Success of these novel approaches individually or in combination will likely enable further breakthroughs in oncofertility, biopreservation research, and clinical practice.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2019–2024). Reported award amounts total $7,034,173. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.